Mitochondrial Toxicity Assessment in Drug Development

This case study discusses the growing importance of mitochondrial toxicity assessment in the drug discovery and development process. It outlines the historical context of drug withdrawals due to mitochondrial toxicity, highlighting the case of troglitazone, an antidiabetic medication linked to severe liver failure. The text details the inadequacies of traditional in vitro cytotoxicity tests and introduces the Glu/Gal assay developed by Luxcel Bioscience, which, despite its effectiveness, has limitations in sensitivity and mechanistic differentiation. Furthermore, it presents advancements in mitochondrial function assessment through the Agilent Seahorse XF assay platform, which allows for real-time monitoring of mitochondrial health. The case study emphasizes the need for more rigorous screening methods to prevent toxic compounds from advancing in drug development. It also compares the performance of the Glu/Gal assay with the XF Mito Stress Test, demonstrating the latter's superior ability to identify mitochondrial toxins, thereby enhancing the drug discovery process.